2.4 Genotyping
The CYP3A5*3 (rs776746) genotype was determined using the Sanger dideoxy DNA sequencing method. Genomic DNA was extracted from EDTA-anticoagulated peripheral blood samples using a commercially available DNA purification kit (EasyPure Blood Genomic DNA Kit, Transgene Biotech, Beijing, China). Subsequently, genomic DNA samples were amplified via polymerase chain reaction (PCR) and sequenced utilizing the ABI 3730XL DNA Sequencer (ABI Co; Majorbio Biotechnology Co.,Ltd., Beijing, China). The forward primer was 5’-CAGCATTTAGTCCTTGTGAG-3’, and the reverse primer was 5’- ACGACACACAGCAACCTTAG-3’. Data analysis was performed using Chromas software (Technelysium, South Brisbane, Australia). Patients carrying the *1 allele (CYP3A5*1/*1 or *1/*3 ) were categorized as CYP3A5 expressers, while those with theCYP3A5 *3/*3 genotype were classified as CYP3A5Non-expressers.